Results 171 to 180 of about 14,917 (240)

Latest update in the management of pancreatic cancer [PDF]

, 2008
Yau, TCC
core  

Correction: Efficacy and prognostic analysis of venetoclax combined with hypomethylating agents for induction therapy in acute myeloid leukemia: a multi-center real-world study on indication-specific stratification, molecular markers, and hematologic toxicities. [PDF]

Cancer Cell Int
Xia L, Qu M, Ge L, Chen Y, Zhou B, Shi T, Liu Y, Ruan M, Xia L, Hong J, Li J, Qian W, Zhang Y, Jiang L, Zhao Y, Tian W, Huang Z, Jin F, Ge J, Yang M, Zeng Q.   +20 more
europepmc   +1 more source

Correction to "Better Response and Prognosis of Venetoclax Plus Hypomethylating Agents Over Intensive Chemotherapy in Young Adults With Newly Diagnosed ASXL1-Mutated Acute Myeloid Leukemia". [PDF]

Cancer Med
europepmc   +1 more source

Emerging applications of hypomethylating agents in the treatment of glioblastoma (Review). [PDF]

Mol Clin Oncol
Silva-Hurtado TJ, Inocencio JF, Yong RL.
europepmc   +1 more source

Does the Timing of Response Impact the Outcome of Relapsed/Refractory Acute Myeloid Leukemia Treated with Venetoclax in Combination with Hypomethylating Agents? A Proof of Concept from a Monocentric Observational Study. [PDF]

J Clin Med
Longo E, Palumbo FE, Duminuco A, Longo L, Vitale DC, Brancati S, Maugeri C, Parisi MS, Palumbo GA, Romano GL, Drago F, Di Raimondo F, Gozzo L, Vetro C.   +13 more
europepmc   +1 more source

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND). [PDF]

Haematologica
Yates SJ, Weiss JJ, Sneider A, Geramita E, Murthy GSG, Badar T, Im A, Lin C, Cheng W, Abaza Y, Swaroop A, Winer ES, Litzow MR, Atallah EL, Patel AA, Shallis RM.   +15 more
europepmc   +1 more source

Significant prognostic improvement in elderly patients with acute myeloid leukemia treated with hypomethylating agents and venetoclax: outcomes from a retrospective real-world analysis. [PDF]

Ann Med
Chen Y, Wang Z, Cai R, Wu Z, Zhou J, Wu L, Wu Y, Zheng J.   +7 more
europepmc   +1 more source

Cancer treatment in the era of targeted therapy: the March is on! [PDF]

, 2011
Chim, JCS
core  

Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML. [PDF]

Blood Adv
Bewersdorf JP, Shimony S, Shallis RM, Liu Y, Berton G, Schaefer EJ, Zeidan AM, Goldberg AD, Stein EM, Marcucci G, Bystrom RP, Lindsley RC, Chen EC, Ramos Perez J, Stein A, Pullarkat V, Aldoss I, DeAngelo DJ, Neuberg DS, Stone RM, Garciaz S, Ball B, Stahl M.   +22 more
europepmc   +1 more source

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations. [PDF]

Blood Cancer J
Jimenez-Vicente C, Cardus A, Castaño-Diez S, Ramil G, Garcia-Avila S, Gomez-Perez L, Esteban D, Arribas I, Sturla AL, Lopez-Guerra M, Martinez-Roca A, Cortes-Bullich A, Perez-Valencia AI, Zugasti I, Monge I, Carcelero E, Vall-Llovera F, Vives S, Sierra J, Nomdedeu J, Oñate G, Garrido A, Pratcorona M, Pomares H, Arnan M, Guijarro F, Diaz-Beya M, Esteve J, Spanish CETLAM Group.   +28 more
europepmc   +1 more source